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The raised nasal transepithelial potential difference (PD) in cystic fibrosis (CF) reflects accelerated














 conductance inhibitors to inhibit nasal PD, including benzamil, an analog of amiloride.









PD%)] and duration of inhibition of PD, defined as the time when drug inhibition of PD had recov-
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channel blocker for CF. 
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Cystic fibrosis (CF) is a common, frequently fatal inherited
disorder in the Caucasian population, affecting about one in
2,500 live births. The major cause of morbidity likely reflects
ion transport abnormalities in airway epithelia, leading to mu-
costasis, bacterial colonization with chronic inflammation, and
irreversible lung damage (1). The airway epithelia of patients
with CF exhibit impaired cAMP-mediated chloride secretion
(2, 3) and increased transcellular sodium absorption (4, 5). It is
likely that these ion transport defects lead to abnormal surface






Because the respiratory epithelium under the inferior tur-
binate of the nose is functionally and morphologically similar
to the ciliated epithelium of the lower airways, the nasal epi-
thelium may serve as a model for studying ion transport in the
lower airways (2, 7, 8). Studies of pharmacotherapy in CF are
most easily initially explored in the nasal cavity because of the





nel blockers, e.g., amiloride, to the nasal epithelium in CF de-
creases the basal potential difference (PD), a parameter which
has been shown to directly correlate with the rate of basal so-
dium absorption in respiratory epithelial (4, 9).
The clinical value of amiloride aerosol therapy is currently
under debate. There are data available which generally show
short-term benefits of inhaled amiloride, particularly in younger
subjects (6, 10–16). However, there are more conflicting results
concerning the possible long-term benefits of amiloride (17,
18). Studies in normal subjects using a filter paper sampling
technique showed that amiloride has a half-life of 35 to 40 min
on airway surfaces (19), raising the speculation that the phar-
macodynamics of the drug were not optimal for longer term
therapy. Recent primary cell culture experiments found that










These results, in agreement with published data from other
epithelia, indicate that benzamil is more potent than amiloride
in inhibiting epithelial sodium transport and, based on improved
pharmacodynamic attributes, could be therapeutically more
effective than amiloride (22). The aim of the present study was
to measure the magnitude and duration of the effect of topi-
cally administered benzamil, as compared with amiloride, on




. Aerosol application of drugs to the nasal or bronchial
epithelium is known to lead to a 10- to 100-fold dilution of
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reason, we employed 10- to 100-fold higher sodium blocker
concentrations in the nebulizer than previously used for the
nasal superfusion technique. Parallel studies were performed
in cultured nasal epithelial preparations, measuring the short




















 SEM). Six patients participated in both the
amiloride and the benzamil protocols. The CF diagnoses were based




 tests and clinical findings. All CF subjects
attended the Pulmonary Department of the Justus Liebig Universität-
Giessen, Pediatric Hospital. The clinical status of the patients played
no role in the selection of patients for the drug/drug concentration
tested. Each subject was without acute symptoms of nasal infection
nor was there nasal polyposis at the time of the PD measurement. For
24 h prior to the study, no other drugs apart from the study drugs were
applied to the nasal epithelium of the patients. The protocols were ap-
proved by the committee for human studies of the Justus Liebig Uni-






. The apparatus consisted of a high-









), connected to a strip-chart recorder (Philips Two Line PM 8272;
Philips, Netherlands). The voltmeter was connected via standard ref-
erence electrodes (Ingold type 373; Ingold, Steinbach, Germany) and
saturated 3 M potassium chloride agar bridges to reference and re-
cording electrodes (7, 9). Both were slowly (2 to 4 ml/h) perfused with
Ringer’s saline by use of infusion pumps (“perfused electrodes”). Bac-









. Nasal PD measurements were made on the
lateral wall and the inferior surface of the turbinate at 0.5 to 4 cm from
the nasal meatus. We connected a nasal speculum to a cold light
source to accomplish visualization. The recording electrode (umbilical








 38 cm) was placed at the
most distal (4-cm) site, and slowly withdrawn in direction of the nares.
The highest (most negative) potential maintaining stability for at least




 (24-gauge plastic catheter). An epicutaneous
reference electrode was placed on the right forearm after a slight
abrasion of the superficial stratum corneum, using fine sandpaper and




. We administered 2 ml of each test so-




 10 min) using a jet nebulizer
(Pari Master Model 84.0100; Pari GmbH, Starnberg, Germany, mass




m; output: 0.6 g/min)
at a mean airflow rate of 5.2 L/min. Amiloride (Synopharm, Ham-
burg, Germany) and benzamil (RBI, Cologne, Germany) solutions
were prepared using sterile filtration and were stored in sterile flasks.
Instead of the usual mouthpiece, an adapter with a nasal mask (Laer-
dal Child No. 3, flow through) was used to assure nasal deposition of
drugs. The patients were instructed to inhale through their nose, and




Before nasal aerosol application of amiloride or benzamil, the maxi-
mal nasal basal PD was measured in each CF patient by surveying
(from 0.5 to 3 cm) the area under the turbinate. Occasionally, consid-
erable differences in baseline PD between the two nostrils were
found, reflecting possible differences in blood flow and/or epithelial
lesions (25). Therefore, for all subjects, the mean of two measure-
ments taken in the nostril with the highest (“most negative”) value




). The nostril with the








postaerosol administration. Following drug administration, PD was




 for up to 6 h, using
anatomic landmarks (i.e., location of the inferior meatus and distance









 3 s) PD in single measurements at each time interval
after which the catheter was removed. This method of data reduction
reflects a modification of the published method (7) but is more easily
performed and less sensitive to unilateral epithelial variances.
Forty-one CF patients were studied, amiloride was administered to
35, and benzamil was administered to 12. Six CF patients received
both benzamil and amiloride. Each CF patient in the amiloride group
received only one dose of drug, and each CF patient in the benzamil
group also received only one dose of drug.






 M amiloride solution was




























 M amiloride to
three CF patients (22 to 28 yr). In the second group of patients (18 to










 M was aerosolized to the nasal surface of










 M benzamil to five CF patients. All
amiloride and benzamil solutions were prepared under sterile condi-

















benzamil solutions, which were diluted in distilled water to avoid drug
precipitation. The amiloride concentrations were chosen equal to those
that had been clinically used as an aerosol for CF in our clinic. Both
benzamil solutions were prepared with the rationale of achieving the
longest possible duration of effect (i.e., nasal sodium transport inhibi-
tion) by aerosolizing the maximal achievable solution concentrations.
For this reason, the benzamil solutions used in this study are not










 M benzamil solu-











zamil is at the limit of solubility in water. The total doses delivered from
the nebulizer (i.e., the volume, 2 ml, in the nebulizer, times concentra-
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The sodium transport inhibitory effects of amiloride and benzamil
in the nasal respiratory epithelium were quantitated by calculation of
the maximal decrease of nasal PD immediately after the aerosol ad-





tion of the PD inhibition was monitored through repetitive (10-min to









the baseline value was detected (or until 6 h passed).
For patient convenience, the PD was measured over a time limited
to 6 h after administration of drug. Based on the assumption that 50%
PD inhibition is a rough threshold for a therapeutic effect, i.e., returns









) was calculated as the time required for the PD af-











Airway epithelial cells were isolated from surgical specimens of nor-
mal subjects and cultured on permeable collagen supports as previ-
ously described (26). Prior studies established that the transepithelial




) generated by these preparations
predominantly reflect amiloride-sensitive sodium absorption (4, 20).





tinuous bilateral perfusion (1 ml/min) of Krebs bicarbonate Ringer













 M, another analog of amiloride, a gen-











were recorded. Following the 5-min drug perfusion, the lumenal su-






















 100) and duration of
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PROC GLM, a general linear models procedure (27). Regression
lines were estimated for both the amiloride and benzamil groups, and









 (% inhibition) and recovery (min)









All nasal PDs were lumen negative with respect to the refer-





 SEM), as referenced to the epicutaneous
electrode, were in agreement with our own previous results (24)
and those published elsewhere in the literature (7, 9, 28, 29).
No differences in baseline PD (predrug) between the amiloride



















247.9 6 2.5 mV for the CF group receiving benzamil
(n 5 12).
Plots of the PD/time curves are shown for the lowest (1023 M,
n 5 16) and for the highest concentration of amiloride (1022 M,
n 5 3) tested (Figure 1A and B, respectively). DPD%s were
67.1 6 2.9% for 1023 M amiloride and 77.3 6 4.3% for 1022 M
amiloride, values that were not significantly different. Figure
1A and B also illustrate the calculations of the average ET50,
which for 1023 M amiloride is 0.7 6 0.02 h, and for 1022 M
amiloride 2.2 6 0.12 h.
Mean data for the high-dose benzamil concentration are
shown in Figure 2. Note that the x-axis in Figure 2 is labeled in
hours as compared with minutes in Figure 1A and B. The ap-
plication of 7 3 1023 M benzamil induces inhibition of PD of
76.2 6 4.2%. The ET50 is estimated to 4.5 6 0.6 h. The nasal
PD was not monitored until return to the initial baseline value
because of the time required (. 6 h) and patient compliance.
Figure 3 displays the dose–effect relationships for amilo-
ride and benzamil with respect to effectiveness. No differences
in DPD% between the six different treatment groups were
found, indicating a maximal initial sodium inhibition by all ap-
plied concentrations of the two drugs (Figure 3A). The “effec-
tive times” (ET50) were determined for each drug concentra-
tion (Figure 3B). ET50 was highly positively correlated with
amiloride concentration (r 5 0.99, p , 0.001). Although only
two concentrations of benzamil were tested, it is evident that
ET50 after administration of benzamil was at least twice as
long at equivalent concentrations of amiloride. ET50 values in
the high-dose benzamil group (7 3 1023 M) were greater than
for both the equivalent amiloride groups (6 3 1023 M and
1022 M). In the low-dose benzamil group (1.7 3 1023 M), ET50
values were higher than in the 1023 M amiloride, and the 3 3
1023 M amiloride groups. When the durations of effect (ET50)
of amiloride and benzamil were compared using a general lin-
ear models procedure, the hypothesis of equal slopes was re-
jected (p , 0.01). Thus, it can be concluded that the durations
of effect for the two drug treatment groups were significantly
different. The complete analyses performed for all four con-
centrations of amiloride and the two concentrations of ben-
zamil tested are shown in Table 1.
In vitro studies revealed an inhibition of Isc by 10
24 M
amiloride, phenamil, or benzamil that ranged from 61 to 77%
of the basal value that was not statistically different among
treatment groups (Figure 4A and Table 1). There was a simi-
lar degree of inhibition of PD in vitro (amiloride 73.4 6 8.0%,
phenamil 58.2 6 3.0%, benzamil 64.8 6 7.0%; n 5 5) in each
group. These data are consistent with reports of the maximally
effective local concentration of each agent from previous stud-
ies of airway epithelia (21). The fact that no drug completely
Figure 1. (A) Effect of 1023 M amiloride (lowest dose) on nasal PD
after nasal aerosol administration as a function of time. PD inhibi-
tion and return to baseline after 55 min are shown. DPD% is the
initial PD inhibition in percent of the baseline (67.1 6 2.9%), ET50
is the effective time of PD inhibition until return to the half-maxi-
mal inhibition (0.7 6 0.02 h). (B) Effect of 1022 M amiloride (high-
est dose) on nasal PD after nasal aerosol administration. PD inhibi-
tion and return to baseline (after z 185 min) are shown. Mean
DPD% is 77.3 6 4.3%, and mean ET50 is 2.2 6 0.12 h.
Figure 2. Effect of 7 3 1023 benzamil on nasal PD after nasal aero-
sol application. PD inhibition (DPD%: 76.2 6 4.2%) and return to
baseline after more than 6 h are shown. ET50 is 4.5 6 0.6 h.
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abolished Isc reflects the fact that chloride secretion is induced
by Na1 channel blockade in normal airway epithelia (4). Upon
perfusion with drug-free solution, the tissues in each drug
treatment group approached full recovery of pretreatment Isc
(and PD), suggesting that each drug is a reversible inhibitor.
However, the time required to recover to the pretreatment
values varied significantly (Figure 4B): The amiloride tested
group returned to baseline Isc most rapidly (32.6 6 6.0 min;
mean 6 SEM, n 5 5), followed by phenamil (55.0 6 11.5 min,
n 5 5), whereas benzamil had the longest duration of effect
(72.4 6 7.8 min, n 5 5, p , 0.05, different from amiloride and
phenamil). Time of recovery of PD paralleled the time of re-
covery of Isc.
DISCUSSION
The overall goal of inhibiting sodium absorption by aero-
solized amiloride therapy for CF lung disease is to normalize
Na1 transport for therapeutically relevant intervals. In previ-
ous clinical investigations, 1023 M and 5 3 1023 M amiloride
solutions were tested as aerosol therapy in patients with CF
lung disease (11, 17, 18, 30). Despite indications of short-term
efficacy of amiloride employing surrogate markers of disease
and certain clinical indices, long-term beneficial effects of
amiloride have been difficult to detect. One possible reason
for this failure to observe a large drug effect of amiloride in
chronic studies is the short duration of amiloride action. The
half-life of inhaled 14C-amiloride on airway surfaces was mea-
sured and found to be short (t1/2 z 35 to 40 min) (19). Our
findings are in agreement with these earlier estimates of the
half-life of aerosolized amiloride on airway surfaces (Figure
1). Two options to enhance inhibition of sodium absorption
for clinical use are available. These include a considerable in-
crease of the daily dose of amiloride, or the use of substances
with a higher affinity to the epithelial sodium channel. A po-
tential benefit of the second option is reduction of the dosing
frequency, which may improve patient compliance.
We used the nasal transepithelial potential difference as an
index to compare the efficacy of a candidate high-affinity Na1
channel blocker, benzamil, with amiloride, to inhibit the ab-
normally high rate of Na1 transport in CF (9, 28). Certain fea-
tures of the PD technique for this study differ from previously
published methods. Previous PD studies have been performed
using a subcutaneous reference electrode (9, 29). We modified
this protocol by using an epicutaneous reference electrode to
extend the time frame (. 5 h) over which drug effects can be
easily monitored (31). Measuring nasal PD with an epicutane-
ous reference electrode yields slightly lower values than with a
subcutaneous reference electrode (9, 29), whereas the vari-
ability in the measurement of PD is similar (31). We also used
a different method to apply amiloride and benzamil to the na-
sal mucosa. Typically, drugs are administered by local super-
fusion with simultaneous PD measurement using a double-
barreled catheter. In this procedure, the PD sensing electrode
is located precisely at the site of constant perfusion of a known
drug concentration (7). However, this methodology requires
extensive experience and is not suitable for long duration
studies. Application of drugs via nasal aerosol with periodic
measurement of PD is a simple alternative that better mimics
Figure 3. (A) Initial inhibition of nasal PD (DPD%) after nasal aero-
sol administration of different concentrations of amiloride [1023 M
(n 5 16), 3 3 1023 M (n 5 9), 6 3 1023 M (n 5 7), 1022 M (n 5
3)] and benzamil [1.7 3 1023 M (n 5 7), and 7 3 1023 M (n 5
5)], expressed as percent of the baseline value (% 6 SEM). No sig-
nificant differences were detected between groups. (B) Duration of
the PD inhibition after nasal aerosol administration of different
concentrations of amiloride [1023 M (n 5 16), 3 3 1023 M (n 5 9),
6 3 1023 M (n 5 7), 1022 M (n 5 3)] and benzamil [1.7 3 1023 M
(n 5 7), and 7 3 1023 M (n 5 5)] expressed as ET50. When the du-
rations of effect (ET50) of amiloride and benzamil are compared us-
ing a general linear models procedure, the slopes are significantly
different (p , 0.01).
TABLE 1
PHARMACODYNAMICS OF SODIUM BLOCKING AGENTS ON NASAL
PD IN CYSTIC FIBROSIS NASAL EPITHELIUM BY FOUR DIFFERENT










Amiloride 1023 M 16 67.1 6 2.9 0.7 6 0.02 z 55
Amiloride 3 3 1023 M 9 74.4 6 2.4 1.1 6 0.04 z 80
Amiloride 6 3 1023 M 7 75.9 6 3.5 1.6 6 0.06 z 130
Amiloride 1022 M 3 77.3 6 4.3 2.2 6 0.12 z 185
Benzamil 1.7 3 1023 M 7 74.9 6 3.0 1.7 6 0.3 z 180
Benzamil 7 3 1023 M 5 76.2 6 4.2 4.5 6 0.6 . 300
* No differences between groups.
† When the durations of effect of amiloride and benzamil were compared using a
general linear models procedure, the slopes were significantly different (p , 0.01).
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the results of the lung aerosol deposition required for clinical
administration. We also chose vehicles (distilled water or iso-
tonic saline) that do not alter nasal PD when nebulized to the
nasal epithelium of normal subjects (10). Repetitive topical
administration of isotonic saline (0.25 ml every 15 min) does
not alter the nasal PD over an 8-h interval (32). Our experi-
ence suggests that topical spray application is a reliable
method that leads to a homogenous deposition of the drug to
the nasal epithelium (10).
A maximal inhibition of basal PD was attained with all
amiloride concentrations (DPD 67–77%, Table 1). Previous
studies using the superfusion technique describe PD inhibition
of 70–80% as the maximal inhibition noted in vivo in CF pa-
tients, indicating that our aerosol delivery system delivers
maximally effective drug concentrations (9). It is not clear
what ion transport processes (i.e., a residual non–cystic fibro-
sis transmembrane-conductance regulator [CFTR]-mediated
Cl2 secretory current or amiloride-insensitive Na1 absorp-
tion) support the remaining potential in vivo in CF patients.
Benzamil at both concentrations tested yielded similar maxi-
mal DPD% as amiloride (Table 1, Figure 3A). Based on the
observation that the DPD% values for the amiloride concen-
trations and the two benzamil concentrations tested were
equal, we conclude that both drugs are capable of maximally
blocking sodium transport.
The data clearly indicate that benzamil is an attractive al-
ternative to amiloride (Figure 3A, B). As noted above, the ef-
ficacy of sodium transport inhibition after benzamil applica-
tion in vivo is similar to amiloride, with a reduction of PD to
values within the normal range (Table 1, Figure 3A). How-
ever, the time to return to baseline (ET50) is significantly
longer for benzamil than for amiloride (Figure 3B). The re-
turn of PD to basal values following drug administration sug-
gests that the inhibition of PD induced by each drug, including
benzamil, reflects blockade of the Na1 channel and not dam-
age to the epithelium. We speculate that the longer time for
the PD to return to basal after benzamil reflects in part the
higher affinity of the drug for the apical sodium channel.
The in vitro studies in cultured nasal epithelium comple-
ment the in vivo comparison of amiloride and benzamil. The
similar magnitude of drug-induced inhibition of Isc (and PD)
in vitro indicates that maximal concentrations of each drug
were studied, and the concordance of drug effects on Isc and
PD in vitro indicate that in vivo PD is an accurate assessment
of actions on Na1 transport (Figure 4A). The recovery of Isc
after removal of each drug application is consistent with a re-
versible inhibition of the Na1 channel. The slower “washout”
of benzamil inhibition is again similar to the in vivo results
(Figure 4B). For the in vitro studies, drug concentration in the
bulk solution was rapidly reduced to negligible levels by per-
fusion with drug-free solution. Therefore, the slower recovery
of Isc (and PD) after benzamil likely reflects a greater affinity
of the agent for the sodium channel. However, slower washout
of the more lipophilic benzamil from a tissue surface compart-
ment contiguous with the Na1 channel cannot be ruled out.
Previous binding studies using tritiated benzamil and phe-
namil, as well as other studies of rank order potency for so-
dium transport inhibition, are consistent with greater binding
affinity and potency for benzamil relative to amiloride in renal
epithelia (22). Very recently, Blank and colleagues compared
the affinities of Na1 channel blockers for the epithelial Na1
channel in CF airway epithelia, including amiloride, and three
of its analogs, benzamil, phenamil, and EIPA [5-(N-ethyl-N-
isopropyl)-29-49-amiloride] (33). Their results showed that
benzamil exhibits the highest affinity for these channels, indi-
cated by the lowest half-maximal blocker concentration (in
CF nasal tissue, 1,000-fold lower than amiloride). Phenamil,
which had been described previously as having an irreversible
effect on other Na1 channels, caused a reversible blockade of
the epithelial Na1 channels. It was less potent than benzamil,
but still 150-fold more potent than amiloride. Although ben-
zamil is more potent than amiloride for Na1 channel inhibi-
tion, benzamil has been reported to be less potent than
amiloride for inhibition of the Na1/H1 exchanger (22). Conse-
quently, benzamil may be the Na1 channel blocker of choice
for further in vivo clinical studies because of its specificity for
the Na1 channel. In vitro studies in sheep and rat tracheal epi-
thelium (34, 35) did describe effects of very high concentra-
tions of benzamil other than inhibition of apical Na1 conduc-
tance, e.g., a decrease of the basolateral potassium conductance
and blockade of cyclic guanosine monophosphate (cGMP)-
gated Na1 channels, but these effects are also seen with amil-
oride.
This is the first report on the sodium transport blocking ef-
fect of benzamil in the respiratory epithelium in vivo. The
Figure 4. (A) Effect of amiloride and analogs, phenamil and ben-
zamil (all 1024 M), on inhibition of the short circuit current (% of
original) of primary culture of normal human respiratory epithe-
lium (n 5 5 in each group), indicating efficacy of inhibiting so-
dium absorption. (B) Times to maximal recovery (Isc, time after
washout) from 5-min administration of amiloride, phenamil, and
benzamil (all 1024 M) to primary culture of normal human respira-
tory epithelium. Percent recoveries were amiloride 84.1 6 7.1%
(mean 6 SEM), phenamil 80.8 6 10.7%, and benzamil 79.4 6
6.9%. *p , 0.05, different from amiloride. #p , 0.05, different
from phenamil and amiloride.
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greater target specificity of benzamil, greater potency, and its
longer duration of sodium transport inhibition might lead to
improved clinical outcomes, compared with amiloride, and re-
duce the frequency of drug administration required for CF pa-
tients. However, there are not yet sufficient safety data de-
scribing benzamil delivered systemically or via aerosol to
estimate its therapeutic index. Compared with amiloride, ben-
zamil contains an additional benzyl moiety instead of one of
the hydrogen atoms of the terminal amino group and is, there-
fore, more lipophilic (22). Potentially increased toxicity com-
pared with amiloride may be a consequence of this property of
the analog. However, systemic central infusion of benzamil in
Dahl S rats has been shown to prevent development of sys-
temic hypertension after saline exposure, while not exhibiting
any toxic effects (36). Complete safety studies will be manda-
tory prior to further clinical studies in the lung. However, in
view of these results and the need for novel and effective drug
treatments for CF patients, further studies of benzamil as ther-
apy for CF lung disease appear warranted.
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